This is an open-label, multi-center study designed to extend the evaluation of the safety, tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS.
Name: KNS-760704
Description: 150 mg Q12H KNS-760704 given orally (300 mg total daily dose)Type: DrugKNS-760704 300 mg/day
Single Group Assignment
There is one SNP
Eligible patients will receive 1 tablet of KNS-760704 150 mg every 12 hours (Q12H) (300 mg total daily dose) for up to 180 weeks. --- Q12H ---